CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of artemisinin by repressing autophagy and inflammation
Ranodeep Chatterjee, Aditya Shukla, Kausiki Chakrabarti, Urmi Chatterji · 2023
Read CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of artemisinin by repressing autophagy and inflammation by Ranodeep Chatterjee, Aditya Shukla, Kausiki Chakrabarti, Urmi Chatterji (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10748408.txt.
Description
Chatterjee leads a team studying how a receptor protein affects breast cancer's response to an antimalarial drug in a 2023 paper. The drug artemisinin also fights cancer in lab studies. The receptor, CLEC12A, normally calms inflammatory signaling.
In tumor-bearing mice, the drug shrank tumors and lowered the receptor's levels. Inflammation and self-eating processes fell while cell death rose. Forcing the receptor back up in cancer cells reversed those effects. Blocking a partner receptor changed nothing, isolating the pathway. Cancer stem cells responded the same way. The authors say the drug's attack runs through this receptor in solid tumors. Repurposing a cheap, safe drug is the appeal. Recurrence risk may also drop.
Catalog record
| CREATOR | Ranodeep Chatterjee, Aditya Shukla, Kausiki Chakrabarti, Urmi Chatterji |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |